Natural killer cell receptors and ligand variants modulate response to tyrosine kinase inhibitors in patients with chronic myeloid leukemia

1. Closa, L.
2. Xicoy, B.
3. Zamora, L.
4. Estrada, N.
5. Colomer, D.
6. Herrero, M.J.
7. Vidal, F.
8. Alvarez-Larrán, A.
9. Caro, J.L.